2019 American Transplant Congress » Poster Session D: Non-Organ Specific: Viral Hepatitis

6:00pm-7:00pm

Evaluating Hepatitis C Treatment after Solid Organ Transplantation

A. J. Burgos¹, R. Yau¹, C. Tunwar², J. A. Goss³, S. Khaderi³, N. L. Sussman⁴

6:00pm-7:00pm

Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience

A. Sharfuddin, S. A. Hussain, T. Taber, D. Mishler, O. Adebiyi, M. S. Yaqub

6:00pm-7:00pm

Hepatitis A Hospitalizations among Kidney Transplant Recipients in the United States: A Nationwide Study

W. Cheungpasitporn¹, C. Thongprayoon², P. Ungprasert³, K. Wijarnpreecha⁴, P. T. Kroner⁴

6:00pm-7:00pm

Hepatitis C Antibody Positive (HCV Ab+)/Nucleic Acid Test Negative (NAT -) Deceased Donor Kidney Transplantation into Hepatitis C Negative (HCV -) Recipients: Is It Safe?

Y. Taehwan, A. Rajab, G. Bumgardner, t. Pesavento, R. Daloul, A. Michaels, K. Washburn, A. El-Hinnawi

6:00pm-7:00pm

Impact of DAA Treatment on Graft Fibrosis in HCV Positive Liver Transplantation

J. Wellington¹, A. Ma², S. Kottilil³, J. Husson³, E. Wilson³, D. Bruno⁴

6:00pm-7:00pm

Introduction of Universal Hepatitis E RNA Screening in Deceased Organ Donors – The UK Experience

I. Ushiro-Lumb¹, K. Tettmar¹, I. Johannessen², K. Simpson², I. Hart³, J. Timms⁴, A. Hale⁵, S. Ijaz⁶, R. Tedder⁶, J. Forsythe¹

6:00pm-7:00pm

Listing Practices and Graft Utilization Lag behind Supply of Hepatitis C Positive Deceased Donors for Liver and Kidney Transplant

C. E. Kling¹, J. D. Perkins², S. W. Biggins³, C. Johnson⁴, A. P. Limaye⁵, L. Sibulesky¹

6:00pm-7:00pm

Long-Term Efficacy of Direct-Acting Antiviral Agents

J. Zhang, W. Sun, J. Lin, Y. Tian, L. Ma, L. Zhang, Y. Zhu

6:00pm-7:00pm

Multicenter Experience Evaluating Outcomes of HCV-Seropositive Donors to HCV-Seronegative Recipients Liver Transplantation

K. Wijarnpreecha¹, B. Aqel², S. Pungpapong¹, C. Taner³, K. Reddy⁴, M. Leise⁵, R. Dickson²

6:00pm-7:00pm

REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis

C. Durand, B. Barnaba, D. Brown, N. Bair, F. Naqvi, M. Bowring, D. Segev, M. Sulkowski, N. Desai

6:00pm-7:00pm

Real World Impact of HCV Viremic Solid Organs on Waitlist Times

N. Kapila¹, A. Ur Rahman¹, K. Gupta², K. Al Khalloufi³, E. Navas³, D. Reino³, S. Ebaid³, N. Agarwal³, J. Shaw³, C. Murgas³, S. Rhazouani³, A. Zeeshan³, A. Tzakis³, C. Sheffield³, J. Vanatta³, X. Zervos³

6:00pm-7:00pm

Renal Function between Tenofovir and Entecavir in Post-Liver Transplanted Hepatitis B Patients

S. Kim, J. Kim, S. Lee, J. Rhu, Y. Chung, S. Kim, J. Joh, S. Lee, G. Choi, J. Park, S. Lee, K. Lee

6:00pm-7:00pm

The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient is Safe and Efficacious

P. Brown¹, Z. Demertzis¹, S. Jafri²

6:00pm-7:00pm

Timing, Duration, and Source of Hepatitis C Virus (HCV) Antibodies (Ab) among HCV-Negative Recipients of an Organ from an HCV-Infected Donor

P. Porrett¹, P. Reese¹, E. Blumberg¹, P. Abt¹, R. Bloom¹, K. Reddy¹, V. Holzmayer², K. Coller², M. Kuhns², G. Cloherty², D. Goldberg¹